Satoru Oya

Satoru Oya

Auto-generated profile, based on publicly available information

Satoru Oya

Department of Pediatrics, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
SOSatoru Oya
Satoru Oya
SOShinya Osone
Shinya Osone
MYMasanori Yoshida
Masanori Yoshida
SNSota Nishimoto
Sota Nishimoto
YTYoshihiro Taura
Yoshihiro Taura
TITomoko Iehara
Tomoko Iehara

11 April 2022
Verified
Preprint
Open access
PDF file
SOSatoru Oya
Satoru Oya
SOShinya Osone
Shinya Osone
MYMasanori Yoshida
Masanori Yoshida
SNSota Nishimoto
Sota Nishimoto
YTYoshihiro Taura
Yoshihiro Taura
TITomoko Iehara
Tomoko Iehara
Erythroid sarcoma is very rare form of pure erythroid leukemia with undetermined biological features. Here, we present an infant with a multifocal erythroid sarcoma, diagnosed because the tumor cells were positive for glycophorin A. After acute myeloid leukemia-oriented chemotherapy and surgical resection followed by cord blood transplantation, he has successfully maintained complete remission without any late effects. Total transcriptome analysis of the tumor identified a novel fusion gene, RCC1-LCK, and high LCK expression levels, suggesting that LCK overexpression was involved in leukemogenesis in this case.

19 May 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
SOSatoru Oya
Satoru Oya
HYHideki Yoshida
Hideki Yoshida
ATAkimasa Tomida
Akimasa Tomida
MMMitsuru Miyachi
Mitsuru Miyachi
SYShigeki Yagyu
Shigeki Yagyu
TITomoko Iehara
Tomoko Iehara
Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.

1 October 2025
Verified
Other
Open access
SOSatoru Oya
Satoru Oya
HYHideki Yoshida
Hideki Yoshida
ATAkimasa Tomida
Akimasa Tomida
MMMitsuru Miyachi
Mitsuru Miyachi
SYShigeki Yagyu
Shigeki Yagyu
TITomoko Iehara
Tomoko Iehara
Table S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

1 October 2025
Verified
Other
Open access
SOSatoru Oya
Satoru Oya
HYHideki Yoshida
Hideki Yoshida
ATAkimasa Tomida
Akimasa Tomida
MMMitsuru Miyachi
Mitsuru Miyachi
SYShigeki Yagyu
Shigeki Yagyu
TITomoko Iehara
Tomoko Iehara
Figure S3 shows expression of CLDN6 and USP44 mRNA in RT cell lines

1 October 2025
Verified
Other
Open access
SOSatoru Oya
Satoru Oya
HYHideki Yoshida
Hideki Yoshida
ATAkimasa Tomida
Akimasa Tomida
MMMitsuru Miyachi
Mitsuru Miyachi
SYShigeki Yagyu
Shigeki Yagyu
TITomoko Iehara
Tomoko Iehara
SALL4 expression in Rhabdoid Tumors in the TARGET database